Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 김이준 | * |
| dc.date.accessioned | 2024-02-01T16:30:48Z | - |
| dc.date.available | 2024-02-01T16:30:48Z | - |
| dc.date.issued | 2024 | * |
| dc.identifier.issn | 2666-3791 | * |
| dc.identifier.other | OAK-34787 | * |
| dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/266926 | - |
| dc.description.abstract | Chondrosarcomas represent the second most common primary bone malignancy. Despite the vulnerability of chondrosarcoma cells to nicotinamide adenine dinucleotide (NAD+) depletion, targeting the NAD+ synthesis pathway remains challenging due to broad implications in biological processes. Here, we establish SIRT1 as a central mediator reinforcing the dependency of chondrosarcoma cells on NAD+ metabolism via HIF-2α-mediated transcriptional reprogramming. SIRT1 knockdown abolishes aggressive phenotypes of chondrosarcomas in orthotopically transplanted tumors in mice. Chondrosarcoma cells thrive under glucose starvation by accumulating NAD+ and subsequently activating the SIRT1-HIF-2α axis. Decoupling this link via SIRT1 inhibition unleashes apoptosis and suppresses tumor progression in conjunction with chemotherapy. Unsupervised clustering analysis identifies a high-risk chondrosarcoma patient subgroup characterized by the upregulation of NAD+ biosynthesis genes. Finally, SIRT1 inhibition abolishes HIF-2α transcriptional activity and sensitizes chondrosarcoma cells to doxorubicin-induced cytotoxicity, irrespective of underlying pathways to accumulate intracellular NAD+. We provide system-level guidelines to develop therapeutic strategies for chondrosarcomas. © 2023 The Author(s) | * |
| dc.language | English | * |
| dc.publisher | Cell Press | * |
| dc.subject | bone tumor | * |
| dc.subject | chondrosarcoma | * |
| dc.subject | HIF-2α | * |
| dc.subject | NAD<sup>+</sup> | * |
| dc.subject | metabolism | * |
| dc.subject | SIRT1 | * |
| dc.subject | targeted therapy | * |
| dc.title | Decoupling NAD+ metabolic dependency in chondrosarcoma by targeting the SIRT1-HIF-2α axis | * |
| dc.type | Article | * |
| dc.relation.issue | 1 | * |
| dc.relation.volume | 5 | * |
| dc.relation.index | SCIE | * |
| dc.relation.index | SCOPUS | * |
| dc.relation.journaltitle | Cell Reports Medicine | * |
| dc.identifier.doi | 10.1016/j.xcrm.2023.101342 | * |
| dc.identifier.wosid | WOS:001170850500001 | * |
| dc.identifier.scopusid | 2-s2.0-85182574588 | * |
| dc.author.google | Suh | * |
| dc.author.google | Jooyeon | * |
| dc.author.google | Kim | * |
| dc.author.google | Hyeonkyeong | * |
| dc.author.google | Min | * |
| dc.author.google | Jiyun | * |
| dc.author.google | Yeon | * |
| dc.author.google | Hyun Ju | * |
| dc.author.google | Hemberg | * |
| dc.author.google | Martin | * |
| dc.author.google | Scimeca | * |
| dc.author.google | Luca | * |
| dc.author.google | Wu | * |
| dc.author.google | Ming-Ru | * |
| dc.author.google | Kang | * |
| dc.author.google | Hyun Guy | * |
| dc.author.google | Yi-Jun | * |
| dc.author.google | Jin-Hong | * |
| dc.contributor.scopusid | 김이준(56714252700) | * |
| dc.date.modifydate | 20260901081000 | * |